Fresh analysis suggests that people who come off popular GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds far faster than those who stop conventional lifestyle regimens.
Published data in a leading medical journal shows that while obese individuals can lose about a fifth of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"Users using these medications should be aware of the potential of fast rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to starting weight in about a year and a half.
Weighing Treatments
The study, which examined 37 of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
Researchers point out that individuals who lose weight through lifestyle changes alone typically have a slower creep back—approximately 100 grams monthly—once they finish.
Understanding the Fast Regain
Experts propose the mode of action of the jabs is key to understanding the heightened rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which controls hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its endogenous hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication results in appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Condition?
Medical guidelines recommend the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians say that, considering the significant potential of relapse, the treatment might need to be ongoing.
This perspective is echoed by pharmaceutical companies, who state that the results "underscore the persistent character of excess weight," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have come off the jabs report a intense resurgence of appetite.
"I experienced something activating and you're instantly starving," said one woman.
This difficulty is compounded if patients have not established permanent dietary or behavioural modifications during treatment.
Significant Use
Figures indicate that millions of adults in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts stress that while the jabs are potent agents for shedding pounds, they are not a permanent cure and long-term success likely depends on integrated behavioural support.
